GRIM19 Protein Composition for HCV Replication Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infections, such as combination therapy with PEG-IFN-α and ribavirin, have limited effectiveness, particularly for certain genotypes, and are associated with significant side effects, necessitating the development of alternative antiviral therapies.
Innovation Solution
A pharmaceutical composition comprising the GRIM19 protein or its fragments, and a gene encoding the protein or fragment, which inhibits HCV replication by overexpression, potentially combined with substances that inhibit DGAT-1, RNA-dependent RNA polymerase, or activate AMP-activated protein kinase, to treat HCV infections regardless of genotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy of PEG-IFN-α and ribavirin is used, then antiviral effect is achieved, but side effects increase and treatment effectiveness is limited for certain genotypes
Solution Approach 1:
The patent extracts and utilizes GRIM19, a specific cellular protein that naturally inhibits HCV replication, as a standalone therapeutic agent. This extraction approach allows the antiviral effect to be achieved through a single targeted mechanism rather than combination therapy, potentially reducing side effects while maintaining effectiveness across different HCV genotypes
Solution Approach 2:
The patent changes the therapeutic parameter from interferon-based combination therapy to GRIM19-based monotherapy. This parameter change shifts the mechanism of action to a different biological pathway, aiming to overcome genotype-specific limitations and reduce the cumulative side effects associated with long-term interferon and ribavirin treatment
2Adaptability or versatility
If PEG-IFN-α and ribavirin combination therapy is used, then treatment coverage is achieved, but treatment effectiveness varies significantly by HCV genotype
Solution Approach 1:
The patent positions GRIM19 as a universal antiviral agent that functions across multiple HCV genotypes. GRIM19 achieves this by targeting a fundamental aspect of HCV replication that is conserved across different genotypes, providing broad-spectrum activity without the genotype-specific limitations of PEG-IFN-α and ribavirin combination therapy
3Adaptability or versatility
If direct-acting antivirals (telaprevir, boceprevir) are used, then treatment options are expanded, but effectiveness is limited for genotype 1b and drug resistance develops
Solution Approach 1:
The patent employs GRIM19 as an intermediary therapeutic agent that acts through a different mechanism than direct-acting antivirals. Rather than directly inhibiting viral proteases or polymerases, GRIM19 modulates cellular pathways to create an environment unfavorable for HCV replication, thereby avoiding the drug resistance issues that plague direct-acting antivirals
Data Source
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.